Our skilled technicians can compound thousands of different products in our state-of-the-art aseptic manufacturing facility. We offer a wide range of drugs, devices and administration routes.

Our dedicated horizon scanning process ensures that promising new therapeutics with imminent MHRA approval undergo a thorough stability study with the R&D team. Meaning compounded products with improved stability should be available to you within weeks of marketing authorisation.

The list below shows some examples of the products available to order, these include Cytotoxics, CIVAS and monoclonal antibody (mAbs) categories.

Contact us for the full list

mAbs

(multiple biosimilars and formulations may be available for some of these products)

Atezolizumab
Avelumab
Bevacizumab
Cemiplimab
Cetuximab
Daratumumab
Dostarlimab
Durvalumab

Infliximab
Ipilimumab
Isatuximab
Natalizumab
Nivolumab
Obinutuzumab
Ocrelizumab
Panitumumab

Pembrolizumab
Phesgo
Polatuzumab Vedotin
Rituximab
Tocilizumab
Trastuzumab
Trastuzumab Deruxtecan
Trastuzumab Emtansine
Vedolizumab

Cytotoxics

Azacitidine
Bortezomib
Carboplatin
Carfilzomib
Cisplatin
Cyclophosphamide
Cytarabine
Daunorubicin

Docetaxel
Doxorubicin
Epirubicin
Eribulin
Etoposide
Fluorouracil
Gemcitabine
Irinotecan

Liposomal Doxorubicin
Oxaliplatin
Paclitaxel
Paclitaxel Albumin(Abraxane)
Pemetrexed Disodium
Vinblastine
Vincristine
Vinorelbine